New Delhi: The Union Government is ready to make a critical change in health care policy by ordering all hospitals involving an unfavorable drug report (ADR) as a mandatory part of the patient’s adoption process, clerks familiar with this matter and showed the documents reviewed by my mint.
This step is designed to create a more robust and consistent system for collecting data on the side effects of the drug, which is essential for early detection of all new or serious risks associated with drugs. The final goal is to strengthen public health by ensuring the safety of drugs on the market.
This new mandate is a key initiative of the Indian (PVPI) pharmacovigillary program, under the supervision of the Indian Pharmacopoeia (IPC) Commission.
Also read | India to rewrite the rules for drug quality to match us, EU, Japan
Pharmacovigilance is a science of monitoring the safety of drugs and detection, evaluation and prevention of side effects. Currently, some hospitals voluntarily include the free PVPI number on their outpatient cards.
However, this new plan will make ADR news compulsory part of the patient’s receiving set. This ensures that doctors and nurses systematically documented any potential side effects related to drugs.
The IPC scientific body discussed this important progress and emphasized the expansion of ADR monitoring centers and the issue of drug safety.
“The plan is that the hospital will now accept this practice of reporting adverse reactions to drugs in patients and will become vigilant about patient health,” the official said.
Also read | India Bolsters Pandemic Realiveness with Zoonotic Diseases Guide 2025
“Previously, reporting was inconsistent, but now every hospital, whether private or government, must accept this practice. This structured approach, inspired by successful models such as the PGI, Chandigarh, makes reporting a routine part of clinical care, allowing us to be more official, and allow us to be more official.” To be more official, and allow us to be more official, and allow us to be more official, and allow us to be more official, and allow us to be more official and allow us to be more official.
Questions sent by spokesperson of the Ministry of Health remained unanswered.
Improved monitoring
Fortis Healthcare spokesman welcomed the government’s decision to order adverse reactions to drug reactions (ADR) and stated that the Indian pharmacovigilatory framework and safety standards of patients would significantly strengthen. “For hospitals, this creates a structured system for monitoring and documentation of drug -related risk, allowing decision and modification of data -based policies. It is an integral part of their clinical responsibility for doctors and nurses, allowing them to recognize and systematically document potential side effects, which ensures transparency and continuous learning.”
The spokesman explained that the identification of ADR includes a clinical process, including careful observation, review of patient history, and the use of standardized tools such as a scale of WHOC causality to verify suspicion suspicion.
Also read | Govt adds 49 drug inspectors. 181 posts still remain unoccupied.
Fortis spokesman stated that compulsory reporting has immediate and long -term benefits for patients. It allows clinical doctors to immediately adjust or interrupt treatment and prevents complications. The data also helps regulatory organs to identify unknown risks and update instructions for the safety of drugs that protect future patients. “We consider ADR report not only as a requirement to comply with regulations, but to be the foundation stone safe, evidence and care focused on the patient,” he said.
The pharmaceutical industry also considered the mandate to be a positive development. Arushi Jain, Director of AKUMS Drugs and Pharmaceuticals, said it was a welcome step that shows a government commitment to patient safety and pharmaceuticals. “By showing mandatory, hospitals will be more careful in monitoring reactions, supporting the culture of transparency and responsibility. It is essential for pharmaceutical companies such as ours because it provides invaluable data that helps us constantly improve our products and services for safer health environment.”
(Tagstotranslate) undesirable reports on reaction to drug
